WO2000049143A1 - Procede d'analyse d'une frequence d'expression genique - Google Patents
Procede d'analyse d'une frequence d'expression genique Download PDFInfo
- Publication number
- WO2000049143A1 WO2000049143A1 PCT/JP2000/000902 JP0000902W WO0049143A1 WO 2000049143 A1 WO2000049143 A1 WO 2000049143A1 JP 0000902 W JP0000902 W JP 0000902W WO 0049143 A1 WO0049143 A1 WO 0049143A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- restriction enzyme
- sequence
- primer
- vector
- cdna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
Definitions
- the present invention relates to a method for analyzing the frequency of expression of a gene.Specifically, in order to capture dynamic changes in gene expression, the type and amount of mRNA expressed from all genes encoding proteins in cells are determined using a microbiological sample. It relates to a method that can be analyzed by using. Background art
- the total number of genes encoding proteins present in the genome is expected to be about 100,000 in humans. In yeast whose whole genome structure has already been elucidated, the total number of genes encoding proteins is estimated to be about 5,000.
- mRNA messenger RNA
- gene expression frequency information the type and amount of the expressed gene (hereinafter, also referred to as “gene expression frequency information”) vary depending on the type and state of the cell. For example, as blood stem cells differentiate into lymphocyte progenitor cells, pre-B cells, B cells, and activated B cells, some genes are commonly expressed in each cell, but show completely different gene expression.
- Gene expression profile analysis Proteins are mainly responsible for the vital activities of cells, and analyzing the type and amount of proteins translated from mRNA is important for gene expression analysis, but at present, obtaining a profile of all proteins Is technically difficult. On the other hand, it is possible to measure all types of mRNA.
- the first reported gene expression profile analysis method is the Body Map method (Gene, 174, 151-158 (1996)).
- the outline of the Body Map method is as follows.
- the poly T sequence on the vector is linked to the poly A tail at the 3 'end of the mRNA, and the cDNA is synthesized using the vector poly T sequence as the primer.
- the cDNA is cut with the restriction enzyme Mbol. Since the Mbol site is one for every 300 base pairs on the cDNA, the cDNA on the vector is split into 300 base pairs on average. At this time, the cDNA from the poly A tail remains bound to the vector.
- the vector containing the cDNA fragment is closed, and it is introduced into Escherichia coli to produce a cDNA library.
- Approximately 1000 clones are arbitrarily selected from the library, and an average of 300 base pairs is determined for each clone. For each clone containing the same sequence from among these sequences, the type and appearance frequency of each sequence are calculated to obtain a gene expression profile. For each cDNA sequence, a homology search (BLAST search) in the data bank is performed, and a clone having the same sequence as a known gene is given the name of the gene. If the sequence is not registered in the bank, it is assumed that the gene corresponding to the sequence does not exist.
- BLAST search a homology search in the data bank is performed, and a clone having the same sequence as a known gene is given the name of the gene. If the sequence is not registered in the bank, it is assumed that the gene corresponding to the sequence does not exist.
- a fragment is further shortened to 11 base pairs or more (referred to as a “tag”), and a large number of these fragments are ligated together and inserted into a vector, thereby creating a library of ligated tags ⁇ :
- a tag represents a gene sequence, and the frequency of appearance of the tag indicates the frequency of expression of the gene.
- the length of a DNA sequence that can be read in a single sequence is about 600 base pairs, so up to about 50 MA sequences can be read in a single sequence.
- gene expression profile analysis can be performed with a maximum efficiency of about 50 times compared to the Body Map method.
- SAGE Serial analysis of gene expression
- Each linker should contain a site for a Class I restriction enzyme such as BsmF I (called a "tagging enzyme"). Cut the cDNA fragment from the beads with a tagging enzyme, smooth the cleavage site, and connect the tag connected to the A linker and the tag connected to the B linker. This is called ditag. Amplify ditags by PCR using primers that recognize A linker and B linker. A large number of amplified ditags are ligated together, integrated into a vector, and sequenced. A maximum of about 50 tag sequences can be obtained in one sequence. This tag sequence information is aggregated to derive the gene expression frequency.
- BsmF I Class I restriction enzyme
- a gene chip method and a gene microarray method.
- a gene fragment is used that is extremely densely arranged (approximately 10 / nrai 2 or more) on a suitable plate (usually a slide glass).
- the chip is hybridized with the fluorescently labeled mRNA, and the mRNA species is Measure type and quantity.
- the SAGE method is the most effective means to measure the expression frequency of all genes in all eukaryotes, but when this method is actually implemented, many problems are encountered, and most methods are used.
- the SAGE method could not be reproduced at the research institution. That is, the SAGE method is difficult to perform and can only be performed by specially trained personnel.
- measurement requires about l ⁇ g of mRNA, and if only a small amount of sample is available, for example, perform measurement on clinical biopsy materials or measure differences in gene expression in minute parts of tissues That is virtually impossible. In addition, there are many measurement errors in principle.
- tags are short (about 13 bp), and misreading at one place may cause the same tag to be judged as a different one, or a different tag to be considered the same.
- the SAGE method is likely to make this mistake. This is because in the SAGE method, a tag is formed by connecting two tags, but the boundary between the tag and the tag becomes unclear at this time. Evening is a short gene fragment cut with restriction enzymes such as BsmFI and Fokl. However, the cleavage sites of these enzymes are not always stable, and the lengths of the excised tags vary. If tags with different lengths are mixed and a tag is connected to form a ditag, a precise tag sequence cannot be obtained.
- the SAGE method has an inevitable disadvantage in principle.
- the SAGE method has an operation of recovering DNA using avidin and biotin beads.However, recovering DNA using avidin and biotin beads without generating contaminants is actually very difficult. It is difficult, and it is very difficult to get an accurate data by the operation of the protocol.
- the SAGE method required a large amount of mRNA to obtain a complete image, and when the sample amount of a clinical sample was limited, sufficient mRNA could not be obtained, making it difficult to perform the SAGE method.
- the gene chip method and the gene microarray method can measure only genes whose structure is known. Therefore, At present, it is not possible to measure the frequency of expression of all genes in all organisms.
- the SAGE method is the most effective means to measure the expression frequency of all genes in all eukaryotes.
- the problems with the SAGE method are as follows: (1) The technique is difficult and can only be performed by specially trained persons. (2) The amount of mRNA required is about l ⁇ g for measurement, and when only a small amount of sample is available, for example, clinical biopsy material cannot be measured. Similarly, it is not possible to measure differences in gene expression in minute parts of the tissue. (3) There are many measurement errors in principle due to the measurement of ditags. Disclosure of the invention
- the present invention has been made in view of the above circumstances, and provides a method that can be easily performed by ordinary researchers and that can perform accurate gene expression frequency analysis from a very small amount of sample.
- the task is to
- the present inventors have conducted intensive studies to solve the above problems, and as a result, synthesized cDNA from mA using a vector primer having a poly T sequence, and obtained a cDNA sequence on the same vector.
- the concatemer is formed by linking the obtained tags via a sequence capable of identifying the end of the tag, and the base sequence of the concatemer is analyzed, whereby the efficiency and the efficiency are improved.
- the present invention provides the following.
- a method for analyzing the expression frequency of a gene comprising the following steps;
- the linear plasmid vector has a single-stranded poly (T) sequence at one of the three termini and a first restriction enzyme recognition sequence inside, and a second restriction fragment near the other terminus.
- a vector primer having an enzyme recognition sequence, a type 11 S restriction enzyme recognition sequence therein, and mRNA derived from a cell whose frequency of gene expression is to be analyzed is annealed to synthesize cDNA.
- step (e) the ligation reaction is performed in the presence of an adapter having one end having the same shape as the end of the tag, whereby the adapter is placed at both ends of the concatemer, and
- the base sequence of the concatemer is determined by cloning into a cloning vector for base sequence determination.
- the vector primer has a cleavage point at or at the same position as the cleavage point of the second restriction enzyme recognition sequence, and is not excised from the vector primer by cleavage with the type IIS restriction enzyme. Having a restriction enzyme recognition sequence of
- the primer downstream of the tag recognizes a fifth restriction enzyme that generates an end having the same shape as the fourth restriction enzyme-cleaved end.
- the vector primer has a base sequence that differs by one base from the fifth restriction enzyme recognition sequence further inside the first restriction enzyme recognition sequence, and The method according to (5), wherein the base sequence different by one base is converted into a fifth restriction enzyme recognition sequence by the used PCR.
- a vector-primer comprises a linear plasmid obtained by cleaving a plasmid having a multiple cloning site at two locations of the same multicloning site, and a primer having the same form as one end of the linear plasmid.
- the method according to any one of (1) to (7), wherein the partial double-stranded DNA having a terminal and having a single-stranded poly-T sequence is linked.
- Figure 1 shows an example of the structure of plasmid DNA (MAGE / PUC19) for making a vector-primer.
- FIG. 2 shows an example of the structure of the vector-primer and the construction process thereof.
- FIG. 3 schematically represents steps (a) and (b) of the method of the invention.
- FIG. 4 schematically represents steps (c) and (d) of the method of the invention.
- FIG. 5 schematically shows step (e) of the method of the present invention and the step of inserting the amplification product obtained in step (e) into the sequence-cloning vector.
- the method of the present invention includes the above steps (a) to (f). Hereinafter, each step will be described.
- a single-stranded plasmid at the 3 'end of one of the linear plasmid vectors A vector having a poly-T sequence of the present invention, a first restriction enzyme recognition sequence therein, a second restriction enzyme recognition sequence near the other end thereof, and a type IIS restriction enzyme recognition sequence therein.
- One primer hereinafter, also referred to as "vector primer for reverse transcription"
- the type IIS restriction enzyme refers to a restriction enzyme that cleaves a specific site apart from the sequence recognized by the restriction enzyme.
- Fig. 2D shows an example of the structure of the vector-primer.
- the vector primer includes, for example, a linear plasmid obtained by cutting a plasmid having a multicloning site at two points of the multicloning site, and one end of the linear plasmid. It can be prepared by ligating a partially double-stranded DNA having the same type of terminus and a single-stranded poly T sequence.
- FIG. 1 shows the structure of MAGE / pUC19 as an example of a plasmid having a multicloning site.
- This primer contains a known cloning vector, PUC19, as its basic structure. A sequence containing various restriction enzyme recognition sites between the EcoRl and Hindi 11 restriction sites of the multicloning site (Z fragment and The sequence is shown in SEQ ID NO: 1.) is inserted.
- MAGE / pUC19 is described as an example in which an Escherichia coli host having a Dam methylation system, for example, a host prepared using the JM109 strain or the like is used. is not.
- the vector having the basic structure is not limited to pUCl9, and other vectors such as pUC18, pBR322, pHSG299, pHSG298, pHSG399, pHSG398, RSFlOlOv pMW119, pMW118, pM219, pMW218, etc. Can be used.
- the host of the vector to be used is not particularly limited as long as it can be applied with a conventional gene recombination technique such as transformation, recovery of the vector from the host, etc., but usually, Escherichia coli Is used.
- the MAGE / pUC19 vector (FIG. 2A) is treated with the restriction enzymes BstXI and Pstl to remove the cut small fragments (FIG. 2B).
- a partially double-stranded DNA having a single-stranded poly-T sequence (poly-T adapter-1 shown in Fig. 2C) was placed at the cut end of BstXI. Rigege. This forms a vector-primer (or a reverse transcription vector-primer) in which a single-stranded poly-T protrudes from one end of the MAGE / pUC19 vector (FIG. 2D).
- the first restriction enzyme is Pmel
- the second restriction enzyme is Bglll
- the type IIS restriction enzyme is Bsgl.
- the recognition sequence of the second restriction enzyme Bglll contains an overlapping bol recognition sequence, which can be cut with Mbol when the Bgill end is linked to the Mbol end.
- the vector primer is designed to include a base sequence that differs by one base from the fourth restriction enzyme (Mbol) recognition sequence further inside the first restriction enzyme (Pmel) recognition sequence (Fig. 3E AMboI).
- the first restriction enzyme recognition sequence of AMboI and vector-primer is derived from a poly (II) adapter.
- the first and second restriction enzymes are not particularly limited as long as they cut the vector primer at one site.
- the type IIS restriction enzyme and the location thereof are not particularly limited as long as the fourth restriction enzyme site is not excised from the vector primer and the cDNA is cut while leaving a part of the upstream side of the cDNA in the vector primer.
- Not restricted Specifically, for example, in addition to the above Bsgl, BsmFI and the like can be mentioned.
- the length of the poly T sequence may be any length that can anneal with the poly A sequence of the mRNA, and is usually about 10 to 50 bases.
- the vector primers as described above are annealed with mRNA derived from the cell whose gene expression frequency is to be analyzed.
- poly-T becomes a primer and cDNA synthesis starts (Fig. 3E).
- the synthesized first-strand cDNA as type II
- the second strand is synthesized, and a double-stranded cDNA can be synthesized (Fig. 3F).
- FIG. 3F A vector primer molecule (cDNA-MAGE / pUC19) in which a large number of cDNAs are bound from a large number of mRNA molecules is shown in FIG. 3F, which is a typical example.
- mRNA is extracted from cells whose gene expression frequency is to be analyzed.
- the cell whose expression frequency is to be analyzed is not particularly limited as long as it has a poly A structure at the 3 ′ end of mRNA in the cell, such as animal or plant tissue cells, yeast or other microorganism cells, etc. be able to.
- prokaryotic mRNA has no poly A (poly (A)) structure at the 3 'end, so it cannot be annealed to poly-T of vector-primer-prime as it is.
- a third primer which does not cleave the vector primer and which has the same form as the cleaved end of the second restriction enzyme, is used to cut the vector primer to which the cDNA thus obtained is bound. Digestion is performed with a restriction enzyme and the second restriction enzyme to excise the upstream side of the cDNA and to close the vector primer.
- the closed loop primer can be amplified by introducing it into an appropriate host, culturing the resulting transformant, and recovering plasmid. The same applies to the closed vector primer obtained in the subsequent steps.However, if the restriction enzyme site that is going to cut the recovered vector primer is not cleaved by Dam methylation, a modification system is used. Use a non-host.
- the third restriction enzyme an enzyme that recognizes four bases is preferable. If the enzyme recognizes 6 bases, there may be no restriction enzyme site in the cDNA sequence. In addition, if the cDNA sequence remaining in the vector-primer is long, the tag obtained by the subsequent operation will be far from the polyA sequence of mA. In such cases, the gene expression information in the database
- EST expressed sequence tag
- MboI, Tail, and the like are examples of the restriction enzyme that recognizes four bases suitable for the present invention.
- the cDNA-coupled vector primer (cMA-MAGE / pUC19) is digested with restriction enzymes BglII and Mbol (FIG. 3G).
- restriction enzymes BglII and Mbol (FIG. 3G).
- MAGE / pUC19 since MAGE / pUC19 has received Dam methylation, it is not cleaved by Mbol, but only the Mbol site in cDNA newly synthesized by reverse transcription is cleaved.
- Figure 3G shows an example in which the cDNA contains three Mbol sites. You.
- the downstream portion from the poly A tail to the first bol site upstream remains connected to the MAGE / pUC19 vector primer, while the other portion, the upstream side of the cDNA is Mbol Separated and removed by cutting.
- MAGE / pUC19 is cut by Bglll.
- the ends cut with Mbol and Bglll have the same shape, and can be connected to each other by a ligation reaction. Therefore, the cDNA-MAGE / pUC19 is closed through these ends by a self-ligation reaction (FIG. 3H).
- the vector primer closed in step (b) is digested with the first restriction enzyme and the type 11S restriction enzyme, and the downstream side of the cDNA is excised leaving a tag consisting of a part of cDNA, Close the vector primer again.
- the closed cDNA-MAGE / pUC19 is digested with restriction enzymes BsgI and PmeI (FIG. 41). Cleavage of these restriction enzymes leaves only about 13 bases farthest from the poly A tail of the 3 'end of the cDNA in the vector primer. The sequence consisting of about 13 bases of this cDNA is called a tag (indicated by “tag” in FIG. 4J).
- PCR is performed using the vector primer closed in step (c) as type I, and oligonucleotides having base sequences corresponding to the respective regions on both sides of the tag in the vector primer as primers. To amplify.
- the tag-containing vector primer is made rust-shaped, and a PCR reaction is performed using primers (for example, SEQ ID NOs: 2 and 3) corresponding to the sequence of the vector portion on both sides of the tag (FIG. 4K).
- primers for example, SEQ ID NOs: 2 and 3
- a DNA fragment containing a tag in the center in this case, LlObp
- Fig. 4L the primer sequence and evening primer
- the primer downstream of the tag contains a recognition sequence for a fifth restriction enzyme that generates an end having the same shape as the end of the fourth restriction enzyme. If the amplified primer is digested with the fourth and fifth restriction enzymes, a concatemer can be efficiently formed.
- the type of the fifth restriction enzyme is not particularly limited, but using the same restriction enzyme as the fourth restriction enzyme simplifies the operation. Further, the same restriction enzyme as the third restriction enzyme may be used as the fourth restriction enzyme. Further, the third, fourth and fifth restriction enzymes may be the same.
- the entire sequence of the cDNA is excised from the vector primer in step (b).
- a base sequence that is different from the fifth restriction enzyme recognition sequence by one base is included further inside the restriction enzyme recognition sequence, and PCR is performed using a primer having the fifth restriction enzyme recognition sequence downstream of the evening restriction enzyme. By doing so, it is necessary to convert a base sequence that differs by one base to a fifth restriction enzyme recognition sequence.
- the third and fourth restriction enzymes are the same, it is necessary to prevent the fourth restriction enzyme recognition site of the vector primer from being cleaved by methylation. In this case, before digestion with the fourth restriction enzyme, the vector-primer closed in step (c) is introduced into a host having no modification system and demodified.
- the ligation reaction of the tag is carried out in the presence of an adapter having one end having the same shape as that of the end of the tag, whereby the adapters are arranged at both ends of the concatemer, whereby an oligo having a sequence corresponding to the sequence of the adapter
- an adapter having one end having the same shape as that of the end of the tag, whereby the adapters are arranged at both ends of the concatemer, whereby an oligo having a sequence corresponding to the sequence of the adapter
- the resulting concatemers are inserted into a closing vector for nucleotide sequencing to facilitate the sequence operation.
- a small fragment containing a tag can be obtained by digesting the amplification product in step (d) with the restriction enzyme Mbol (FIG. 5M).
- the evening fragment obtained here is sandwiched between known DNA sequences, that is, GATC and AAACG, and it is possible to clearly identify which portion is evening. Since the Mbol sites are exposed at both ends of this tag sequence, the concatemers can be formed by linking the evening dogs by the ligation reaction (Fig. 5M).
- the nucleotide sequence of the concatemer obtained as described above contains tags derived from many cDNA molecules, and the type and frequency of the tags appearing in the nucleotide sequence are examined. This makes it possible to analyze the expression frequency of the gene from which the cDNA is derived.
- the type of tag can be determined by searching the database for information on the known partial sequence (EST) of mMA.
- the orientation of the tag in the concatemer is undefined, so the sequence analysis considers not only the sequence of one strand but the sequence of the opposite strand. I do.
- a ditag is not formed unlike the SAGE method, and each tag is sandwiched between known DNA fragments, so that a tag can be prevented from being continuous with another tag.
- the problem that the boundaries of tags become ambiguous has been solved Is done.
- the sample can be amplified by performing PCR multiple times, it is possible to analyze even a small amount of mRNA.
- vector-1 primers to synthesize cDNA in a form fused to vector-1, analysis can be performed without using avidin or biotin beads.
- the MAGE / pUC19 vector (Fig. 2A) was treated with the restriction enzymes BstXI and Pstl to remove the cut small fragments (Fig. 2B).
- a partially double-stranded DNA having a single-stranded poly-T sequence (poly-T adapter shown in FIG. 2C) was ligated to the cut end by BstXI (FIG. 2D).
- the first restriction enzyme is Pmel
- the second restriction enzyme is Bglll
- the type IIS restriction enzyme is Bsgl (FIG. 3E).
- the above-mentioned vector primer (0.2 ⁇ g) and the above-mentioned mouse liver-derived mRNA (0.97 ⁇ g) were annealed to synthesize cDNA, and then the second strand was synthesized using the synthesized first strand cDNA as type II (Fig. 3 F). Then, gene expression frequency analysis was performed using an amount corresponding to 1/40 of the obtained cDNA (equivalent to 0.025 ⁇ g of mRNA) as a material.
- the vector primer to which the cDNA obtained as described above was ligated was digested with the second restriction enzyme Bglll and the third restriction enzyme Mbol (FIG. 3G).
- the Mbo I terminus and Bgl 11 terminus of cDNA-AGE / pUC19 were ligated and closed by a self-ligation reaction (FIG. 3H).
- the closed vector primer was digested with Bsgl and Pmel, blunted by T4 MA polymerase treatment, and the vector primer was closed again (FIG. 41 to FIG. 41).
- K An oligonucleotide having a base sequence corresponding to the respective regions on both sides of the tag in the vector-primer, with this closed vector-primer as type II.
- the above-mentioned PCR amplification product is digested with Mbol to excise the tag, and an adapter which is annealed with an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 4 or 5 is added so that the tag: adapter becomes 8: 1.
- a ligation reaction was performed to form a concatemer in the evening (Fig. 5M). This concatemer was amplified by PCR using a primer having the nucleotide sequence shown in SEQ ID NO: 6.
- the PCR reaction consists of denaturation (95 ° C, 3 minutes), annealing (40 ° C, 3 minutes), polymerase reaction (72 ° C, 1 minute), followed by 5 cycles, followed by denaturation (95 ° C , 0.3 min), annealing and extension reaction (72 ° C, 1 min) were performed for 60 cycles.
- the amplification product was digested with the restriction enzyme Notl, inserted into the Notl site of the sequencing-cloning vector pKF3, and the nucleotide sequence was determined.
- the expression frequency of a gene can be simply, reliably, and accurately analyzed.
- the gene expression analysis method of the present invention is useful for life science research, in particular, by analyzing the difference in gene expression in specific organs or cells between healthy and sick people, it is possible to develop therapeutic methods for diseases and Useful for developing diagnostic methods. For example, by analyzing the difference between the expressed genes in the liver of healthy humans and the liver of hepatitis by this method, it is possible to find genes whose expression is specifically increased or decreased in hepatitis. By investigating the role of these genes in the liver, drugs for inhibiting or promoting the function of this gene can be developed for the treatment of hepatitis.
- the gene itself, an antisense oligonucleotide designed from the gene structure, or a protein obtained by expressing the gene can be used for the treatment of hepatitis.
- a therapeutic method can be developed by using the method of the present invention for diseases for which the mechanism of onset is unknown.
- a gene whose expression fluctuates in a disease-specific manner can be found by the method of the present invention, it will be possible to develop not only a treatment but also a diagnostic method for a disease.
- it can be used not only for medical applications, but also for finding useful genes in all eukaryotes.
- a yeast suitable for beer production is bred by mutation
- changes in gene expression between the parent strain and the mutant strain are analyzed by the method of the present invention, and a gene whose expression has changed due to the mutation can be identified.
- a better beer-producing yeast can be created by comprehensively manipulating the genes that are advantageous for beer production thus obtained.
- an amino acid-producing bacterium such as Escherichia coli or corynepacterium
- a better amino acid-producing bacterium can be created.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00904009A EP1156107B1 (en) | 1999-02-17 | 2000-02-17 | Method for analyzing gene expression frequency |
AT00904009T ATE275196T1 (de) | 1999-02-17 | 2000-02-17 | Verfahren zur analyse der genexpressions-frequenz |
US09/926,028 US6806049B1 (en) | 1999-02-17 | 2000-02-17 | Method for analyzing gene expression frequency |
DE60013410T DE60013410T2 (de) | 1999-02-17 | 2000-02-17 | Verfahren zur analyse der genexpressions-frequenz |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP03853899A JP3924976B2 (ja) | 1999-02-17 | 1999-02-17 | 遺伝子の発現頻度の解析方法 |
JP11/38538 | 1999-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000049143A1 true WO2000049143A1 (fr) | 2000-08-24 |
Family
ID=12528071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/000902 WO2000049143A1 (fr) | 1999-02-17 | 2000-02-17 | Procede d'analyse d'une frequence d'expression genique |
Country Status (7)
Country | Link |
---|---|
US (1) | US6806049B1 (ja) |
EP (1) | EP1156107B1 (ja) |
JP (1) | JP3924976B2 (ja) |
AT (1) | ATE275196T1 (ja) |
DE (1) | DE60013410T2 (ja) |
DK (1) | DK1156107T3 (ja) |
WO (1) | WO2000049143A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004097158A (ja) * | 2002-09-12 | 2004-04-02 | Kureha Chem Ind Co Ltd | 発現遺伝子同定用cDNAタグの作成方法、及び該cDNAタグを用いる遺伝子発現解析方法 |
JP4034317B2 (ja) | 2005-03-29 | 2008-01-16 | 富士通株式会社 | 画像符号化装置 |
AU2007341981A1 (en) * | 2006-12-29 | 2008-07-10 | The Salk Institute For Biological Studies | Methods for enhancing exercise performance |
WO2009091719A1 (en) | 2008-01-14 | 2009-07-23 | Applera Corporation | Compositions, methods, and kits for detecting ribonucleic acid |
EP2910649A1 (en) | 2009-08-24 | 2015-08-26 | National University Corporation Kanazawa University | Detection of pancreatic cancer by gene expression profiling |
JP7445334B1 (ja) | 2022-09-05 | 2024-03-07 | 株式会社キュービクス | 膵臓癌に特異的な遺伝子発現パターンの検出及びca19-9の測定の併用による膵臓癌の検出 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997010363A1 (en) * | 1995-09-12 | 1997-03-20 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
US6136537A (en) * | 1998-02-23 | 2000-10-24 | Macevicz; Stephen C. | Gene expression analysis |
-
1999
- 1999-02-17 JP JP03853899A patent/JP3924976B2/ja not_active Expired - Fee Related
-
2000
- 2000-02-17 WO PCT/JP2000/000902 patent/WO2000049143A1/ja active IP Right Grant
- 2000-02-17 DE DE60013410T patent/DE60013410T2/de not_active Expired - Lifetime
- 2000-02-17 US US09/926,028 patent/US6806049B1/en not_active Expired - Fee Related
- 2000-02-17 DK DK00904009T patent/DK1156107T3/da active
- 2000-02-17 EP EP00904009A patent/EP1156107B1/en not_active Expired - Lifetime
- 2000-02-17 AT AT00904009T patent/ATE275196T1/de not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997010363A1 (en) * | 1995-09-12 | 1997-03-20 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
Non-Patent Citations (3)
Title |
---|
BERANGERE VIRLON ET AL.: "Serial microanalysis of renal transcriptomes", PROC. NATL. ACAD. SCI. USA,, vol. 96, no. 26, 21 December 1999 (1999-12-21), pages 15286 - 15291, XP002927763 * |
CZARNOTA G.J. ET AL.: "High resolution microanalysis and three-dimensioanl mucleosome structure associated with transcribing chromatin", MICRON.,, vol. 28, no. 6, December 1997 (1997-12-01), pages 419 - 431, XP002929046 * |
GIGUERE S. ET AL.: "Quantitation of equine cytokine mRNA expression by reverse transcription-competitive polymerase chain reaction", VET IMMUNOL. IMMUNOPATHOL.,, vol. 67, no. 1, 4 January 1999 (1999-01-04), pages 1 - 15, XP000925534 * |
Also Published As
Publication number | Publication date |
---|---|
EP1156107A1 (en) | 2001-11-21 |
JP3924976B2 (ja) | 2007-06-06 |
US6806049B1 (en) | 2004-10-19 |
ATE275196T1 (de) | 2004-09-15 |
DE60013410T2 (de) | 2005-09-15 |
EP1156107A4 (en) | 2002-09-25 |
DE60013410D1 (de) | 2004-10-07 |
EP1156107B1 (en) | 2004-09-01 |
DK1156107T3 (da) | 2004-12-06 |
JP2000232888A (ja) | 2000-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107586835B (zh) | 一种基于单链接头的下一代测序文库的构建方法及其应用 | |
US6472207B1 (en) | Method for producing tagged genes, transcripts, and proteins | |
US6395478B1 (en) | Identification and comparison of protein-protein interactions that occur in populations and indentification of inhibitors of these interactors | |
JP2001514488A (ja) | 遺伝子の量的発現を分析する方法 | |
JP4644685B2 (ja) | 塩基配列タグの調製方法 | |
WO2006085616A1 (ja) | 核酸配列増幅方法 | |
KR20150141944A (ko) | 혼합물 중 핵산의 서열분석 방법 및 그와 관련된 조성물 | |
CN108300767A (zh) | 一种核酸复合体中核酸区段相互作用的分析方法 | |
TW200948969A (en) | Expression-linked gene discovery | |
CN113337502B (zh) | 一种gRNA及其用途 | |
JPH0923885A (ja) | 遺伝子発現ライブラリー及びその製造法 | |
KR101913735B1 (ko) | 차세대 염기서열 분석을 위한 시료 간 교차 오염 탐색용 내부 검정 물질 | |
WO2000049143A1 (fr) | Procede d'analyse d'une frequence d'expression genique | |
JP2002530119A (ja) | 任意プライマーおよび低ストリンジェンシーを用いるヌクレオチド配列決定法 | |
WO2022185664A1 (ja) | 翻訳促進剤、翻訳鋳型mRNA、転写鋳型DNA、翻訳鋳型mRNAの生産方法、および、タンパク質の生産方法 | |
JP4403069B2 (ja) | クローニングおよび分析のためのmRNAの5’末端の使用方法 | |
JP2004187606A (ja) | 核酸アイソフォームの同定、分析および/またはクローニング方法 | |
CN104419756B (zh) | 检测哺乳动物基因组三核苷酸重复序列的方法及其应用 | |
JP5322141B2 (ja) | 5’領域ディファレンシャルディスプレー法 | |
JP6417603B2 (ja) | Rnaの末端領域に対応する核酸の塩基配列を解読する方法およびdnaエレメントの分析方法 | |
AU2004295532A1 (en) | Method of obtaining gene tag | |
WO2008015975A1 (fr) | Procédé d'amplification d'un fragment d'adn | |
WO2024119461A1 (en) | Compositions and methods for detecting target cleavage sites of crispr/cas nucleases and dna translocation | |
TW200411069A (en) | Detection of evolutionary bottlenecking by dna sequencing as a method to discover genes of value | |
EP3763811A1 (en) | Reverse transcriptase and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09926028 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000904009 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000904009 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000904009 Country of ref document: EP |